[go: up one dir, main page]

MX2023011332A - Tratamientos combinados para el melanoma. - Google Patents

Tratamientos combinados para el melanoma.

Info

Publication number
MX2023011332A
MX2023011332A MX2023011332A MX2023011332A MX2023011332A MX 2023011332 A MX2023011332 A MX 2023011332A MX 2023011332 A MX2023011332 A MX 2023011332A MX 2023011332 A MX2023011332 A MX 2023011332A MX 2023011332 A MX2023011332 A MX 2023011332A
Authority
MX
Mexico
Prior art keywords
melanoma
combination treatments
combination
treatments
inhibitor
Prior art date
Application number
MX2023011332A
Other languages
English (en)
Inventor
Jeeyun Lee
Simon Andrew Smith
Emma Jane Dean
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2023011332A publication Critical patent/MX2023011332A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta memoria descriptiva divulga el uso de un inhibidor de ATR en combinación con un inhibidor de puntos de control inmunitarios para el tratamiento del melanoma en un paciente que ha recibido previamente inmunoterapia.
MX2023011332A 2021-03-26 2022-03-25 Tratamientos combinados para el melanoma. MX2023011332A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166295P 2021-03-26 2021-03-26
US202163208728P 2021-06-09 2021-06-09
PCT/EP2022/057895 WO2022200557A1 (en) 2021-03-26 2022-03-25 Combination treatments for melanoma

Publications (1)

Publication Number Publication Date
MX2023011332A true MX2023011332A (es) 2023-10-03

Family

ID=81449142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011332A MX2023011332A (es) 2021-03-26 2022-03-25 Tratamientos combinados para el melanoma.

Country Status (11)

Country Link
US (1) US20240197748A1 (es)
EP (1) EP4313057A1 (es)
JP (1) JP2024512558A (es)
KR (1) KR20230162030A (es)
AU (2) AU2022245277B8 (es)
BR (1) BR112023019433A2 (es)
CA (1) CA3213407A1 (es)
IL (1) IL306028A (es)
MX (1) MX2023011332A (es)
TW (1) TW202304458A (es)
WO (1) WO2022200557A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025233224A1 (en) * 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
KR20210143932A (ko) * 2013-09-11 2021-11-29 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체
KR20230009481A (ko) * 2020-05-11 2023-01-17 아스트라제네카 아베 암 치료를 위한 atr 저해제

Also Published As

Publication number Publication date
AU2022245277A1 (en) 2023-11-02
EP4313057A1 (en) 2024-02-07
AU2025252564A1 (en) 2025-11-27
AU2022245277B1 (en) 2025-07-17
CA3213407A1 (en) 2022-09-29
AU2022245277A9 (en) 2023-11-16
WO2022200557A1 (en) 2022-09-29
US20240197748A1 (en) 2024-06-20
AU2022245277B8 (en) 2025-08-07
IL306028A (en) 2023-11-01
TW202304458A (zh) 2023-02-01
KR20230162030A (ko) 2023-11-28
JP2024512558A (ja) 2024-03-19
BR112023019433A2 (pt) 2023-10-24

Similar Documents

Publication Publication Date Title
MX2022014104A (es) Inhibidores de atr para el tratamiento del cancer.
MX2022008868A (es) Tratamiento del cancer con tg02.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
PH12020550936A1 (en) Combination drug including tlr7 agonist
ZA202202797B (en) Anti-cd47 and anti-cd20 based treatment of blood cancer
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
NZ749727A (en) A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
ZA202102604B (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
MX2022002699A (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MX2022004577A (es) Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
MX2024008461A (es) Metodos para tratar trastornos linfoproliferativos malignos.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
WO2015116729A3 (en) Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
MX2023011332A (es) Tratamientos combinados para el melanoma.
MX2019013096A (es) Peptidos para el tratamiento de diabetes.
WO2019204332A3 (en) Pak4 inhibitors and methods of use
PH12021551949A1 (en) Cancer treatment
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MY200803A (en) Mpo inhibitors for use in medicine